Figure 10 | Scientific Reports

Figure 10

From: Identification of a bile acid and bile salt metabolism-related lncRNA signature for predicting prognosis and treatment response in hepatocellular carcinoma

Figure 10The alt text for this image may have been generated using AI.

Comparison of the sensitivity of the low- and high-risk groups to chemotherapeutic and targeted drugs. (a–h) Estimated IC50 of chemotherapeutic drugs Bortezomib, Cisplatin, Docetaxel, Doxorubicin, Gemcitabine, Mitomycin.C, Paclitaxel and Rapamycin in the low- and high-risk groups. (i–l) Estimated IC50 of targeted drugs Erlotinib, Gefitinib, Tipifarnib and Sorafenib in the low- and high-risk groups. IC50 half-maximal inhibitory concentration.

Back to article page